Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man

Journal of Clinical Pharmacology

Volumn 43, Issue 3, 2003, Pages 268-276

  Agrawal, Nancy G B ^a   Porras, Arturo G ^a   Matthews, Catherine Z ^a   Rose, Mark J ^a   Woolf, Eric J ^a   Musser, Bret J ^a   Dynder, Andrea L ^a   Mazina, Katherine E ^a   Lasseter, Kenneth C ^b   Hunt, Thomas L ^c   Schwartz, Jules I ^a   McCrea, Jacqueline B ^a   Gottesdiener, Keith M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Clinical Pharmacology Associates Miami   (United States)

^c Pharmaceutical Product Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; FEMALE; FLATULENCE; FOOD DRUG INTERACTION; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INSOMNIA; LIPID DIET; MALE; NAUSEA; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; TABLET; TASTE DISORDER; THIRST; URINE COLOR; VERTIGO;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRIDINES; SULFONES; TABLETS; TIME FACTORS;

EID: 0037372154     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003251122     Document Type: Article

References (13)

1. Vane JR, Botting RM: The history of anti-inflammatory drugs and their mechanism of action, in: Bazan N, Botting J, Vane JR (eds.), New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules. London: Kluwer, 1996.
2. Smith WL, DeWitt DL: Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Seminars in Nephrology 1995;15:179-194.
3. Donnelly MT, Hawkey CJ: COX-II inhibitors - a new generation of safer NSAIDs? Aliment Pharmacol Ther 1997;11:227-236.
4. Jouzeau J-Y, Terlain B, Abid A, Nedelec E, Netter P: Cyclooxygenase isoenzymes: how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997;53:563-582.
5. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR: Selectivity of nonsteroidal and inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11693-11697.
6. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
7. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-1933.
8. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al: Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296:558-566.
9. Matthews CZ, Woolf EJ, Lin L, Fang W, Hsieh J, Ha S, et al: High-throughput, semi-automated determination of a cyclooxygenase II inhibitor in human plasma and urine using solid-phase extraction in the 96-well format and high-performance liquid chromatography with post-column photochemical derivatization-fluorescence detection. J Chromatogr B 2001;751:237-246.
10. Yeh KC, Remphrey K: A simplex optimization program. Pharm Res 1990;7:S244.
11. Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al: Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000;17:1278-1283.
12. Agrawal NGB, Porras AG, Matthews CZ, Woolf EJ, Miller JL, Mukhopadhyay S, et al: Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J Clin Pharmacol 2001;41:1106-1110.
13. Dallob A, Hawkey CJ, Greenberg H, Wight N, DeSchepper P, Waldman S, et al: Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol; manuscript accepted for publication.